Advances in the therapy of BRAFV600E metastatic colorectal cancer

Zhaohui Jin, Frank A Sinicrope

Research output: Contribution to journalReview article

Abstract

Introduction: BRAFV600E metastatic colorectal cancer (CRC) is an aggressive tumor subset with an approximate 8% incidence. In these patients, standard chemotherapy has limited efficacy, and the recent development of novel-targeted treatment regimens may significantly improve clinical outcome. Area covered: This review provides an overview of available data regarding advances in the first–line treatment of BRAFV600E metastatic CRC including patient tumors with microsatellite instability. The implications of BRAFV600E in earlier stage CRC are also discussed. Expert opinion: Recently, significant progress has been achieved in improving tumor response rates using a novel-targeted regimen in patients with BRAFV600E metastatic CRC. The implications of BRAFV600E in non-metastatic CRC are also becoming more evident and remains an area of ongoing investigation. The majority of CRCs with microsatellite instability high are sporadic and frequently harbor BRAFV600E. All patients with microsatellite instability high metastatic CRCs, irrespective of BRAFV600E, are candidates for immune checkpoint inhibitors. The optimal sequencing of treatment regimens for patients with BRAFV600E metastatic CRCs is an important area for future research.

Original languageEnglish (US)
Pages (from-to)823-829
Number of pages7
JournalExpert review of anticancer therapy
Volume19
Issue number9
DOIs
StatePublished - Sep 2 2019

Fingerprint

Colorectal Neoplasms
Microsatellite Instability
Therapeutics
Neoplasms
Expert Testimony
Drug Therapy
Incidence

Keywords

  • BRAF
  • circulating tumor DNA
  • colorectal cancer
  • microsatellite instability
  • targeted treatment

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Advances in the therapy of BRAFV600E metastatic colorectal cancer. / Jin, Zhaohui; Sinicrope, Frank A.

In: Expert review of anticancer therapy, Vol. 19, No. 9, 02.09.2019, p. 823-829.

Research output: Contribution to journalReview article

@article{aec40198e8924033943bb2398b7a31a9,
title = "Advances in the therapy of BRAFV600E metastatic colorectal cancer",
abstract = "Introduction: BRAFV600E metastatic colorectal cancer (CRC) is an aggressive tumor subset with an approximate 8{\%} incidence. In these patients, standard chemotherapy has limited efficacy, and the recent development of novel-targeted treatment regimens may significantly improve clinical outcome. Area covered: This review provides an overview of available data regarding advances in the first–line treatment of BRAFV600E metastatic CRC including patient tumors with microsatellite instability. The implications of BRAFV600E in earlier stage CRC are also discussed. Expert opinion: Recently, significant progress has been achieved in improving tumor response rates using a novel-targeted regimen in patients with BRAFV600E metastatic CRC. The implications of BRAFV600E in non-metastatic CRC are also becoming more evident and remains an area of ongoing investigation. The majority of CRCs with microsatellite instability high are sporadic and frequently harbor BRAFV600E. All patients with microsatellite instability high metastatic CRCs, irrespective of BRAFV600E, are candidates for immune checkpoint inhibitors. The optimal sequencing of treatment regimens for patients with BRAFV600E metastatic CRCs is an important area for future research.",
keywords = "BRAF, circulating tumor DNA, colorectal cancer, microsatellite instability, targeted treatment",
author = "Zhaohui Jin and Sinicrope, {Frank A}",
year = "2019",
month = "9",
day = "2",
doi = "10.1080/14737140.2019.1661778",
language = "English (US)",
volume = "19",
pages = "823--829",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "9",

}

TY - JOUR

T1 - Advances in the therapy of BRAFV600E metastatic colorectal cancer

AU - Jin, Zhaohui

AU - Sinicrope, Frank A

PY - 2019/9/2

Y1 - 2019/9/2

N2 - Introduction: BRAFV600E metastatic colorectal cancer (CRC) is an aggressive tumor subset with an approximate 8% incidence. In these patients, standard chemotherapy has limited efficacy, and the recent development of novel-targeted treatment regimens may significantly improve clinical outcome. Area covered: This review provides an overview of available data regarding advances in the first–line treatment of BRAFV600E metastatic CRC including patient tumors with microsatellite instability. The implications of BRAFV600E in earlier stage CRC are also discussed. Expert opinion: Recently, significant progress has been achieved in improving tumor response rates using a novel-targeted regimen in patients with BRAFV600E metastatic CRC. The implications of BRAFV600E in non-metastatic CRC are also becoming more evident and remains an area of ongoing investigation. The majority of CRCs with microsatellite instability high are sporadic and frequently harbor BRAFV600E. All patients with microsatellite instability high metastatic CRCs, irrespective of BRAFV600E, are candidates for immune checkpoint inhibitors. The optimal sequencing of treatment regimens for patients with BRAFV600E metastatic CRCs is an important area for future research.

AB - Introduction: BRAFV600E metastatic colorectal cancer (CRC) is an aggressive tumor subset with an approximate 8% incidence. In these patients, standard chemotherapy has limited efficacy, and the recent development of novel-targeted treatment regimens may significantly improve clinical outcome. Area covered: This review provides an overview of available data regarding advances in the first–line treatment of BRAFV600E metastatic CRC including patient tumors with microsatellite instability. The implications of BRAFV600E in earlier stage CRC are also discussed. Expert opinion: Recently, significant progress has been achieved in improving tumor response rates using a novel-targeted regimen in patients with BRAFV600E metastatic CRC. The implications of BRAFV600E in non-metastatic CRC are also becoming more evident and remains an area of ongoing investigation. The majority of CRCs with microsatellite instability high are sporadic and frequently harbor BRAFV600E. All patients with microsatellite instability high metastatic CRCs, irrespective of BRAFV600E, are candidates for immune checkpoint inhibitors. The optimal sequencing of treatment regimens for patients with BRAFV600E metastatic CRCs is an important area for future research.

KW - BRAF

KW - circulating tumor DNA

KW - colorectal cancer

KW - microsatellite instability

KW - targeted treatment

UR - http://www.scopus.com/inward/record.url?scp=85071972790&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071972790&partnerID=8YFLogxK

U2 - 10.1080/14737140.2019.1661778

DO - 10.1080/14737140.2019.1661778

M3 - Review article

C2 - 31455117

AN - SCOPUS:85071972790

VL - 19

SP - 823

EP - 829

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 9

ER -